Omeros | OMER - Sales Revenues


Omeros reported $0 in Sales Revenues for its fiscal quarter ending in March of 2022.





Sales Change Date
Adma Biologics USD 139.16M 4.94M Dec/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Gilead Sciences USD 7.93B 130M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Rockwell Medical USD 25.83M 3.15M Jun/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xoma USD 25K 5M Sep/2024